Stock Scorecard



Stock Summary for Arcturus Therapeutics Holdings Inc (ARCT) - $12.61 as of 5/5/2025 7:29:55 PM EST

Total Score

10 out of 30

Safety Score

32 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ARCT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ARCT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ARCT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ARCT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ARCT (32 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ARCT

Earnings Preview: Arcturus Therapeutics ( ARCT ) Q1 Earnings Expected to Decline 5/5/2025 2:00:00 PM
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate 4/11/2025 3:49:00 PM
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at 9.4% CAGR: Verified Market Research® 3/17/2025 2:00:00 PM
Arcturus Therapeutics ( ARCT ) Reports Q4 Loss, Misses Revenue Estimates 3/6/2025 10:15:00 PM
Axsome ( AXSM ) Surges 20.2%: Is This an Indication of Further Gains? 2/11/2025 8:33:00 AM
Arcturus Therapeutics ( ARCT ) Reports Q3 Loss, Lags Revenue Estimates 11/7/2024 10:55:00 PM
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect 11/4/2024 3:05:00 PM
Arcturus Therapeutics ( ARCT ) Upgraded to Buy: What Does It Mean for the Stock? 10/30/2024 4:00:00 PM
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty 10/1/2024 2:46:00 PM
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Arcturus Therapeutics ( NASDAQ:ARCT ) , Pfizer ( NYSE:PFE ) , CSL ( OTC:CSLLY ) 9/30/2024 3:12:00 PM

Financial Details for ARCT

Company Overview

Ticker ARCT
Company Name Arcturus Therapeutics Holdings Inc
Country USA
Description Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 6/13/2025

Stock Price History

Last Day Price 12.61
Price 4 Years Ago 37.01
Last Day Price Updated 5/5/2025 7:29:55 PM EST
Last Day Volume 240,286
Average Daily Volume 425,062
52-Week High 45.00
52-Week Low 8.04
Last Price to 52 Week Low 56.84%

Valuation Measures

Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE 1.83
Free Cash Flow Ratio 1.44
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 4.67
Total Cash Per Share 8.74
Book Value Per Share Most Recent Quarter 8.89
Price to Book Ratio 1.44
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 2.28
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 27,119,800
Market Capitalization 341,980,678
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -172.30%
Reported EPS 12 Trailing Months -3.00
Reported EPS Past Year 0.00
Reported EPS Prior Year -3.01
Net Income Twelve Trailing Months -80,941,000
Net Income Past Year -80,941,000
Net Income Prior Year -29,725,000
Quarterly Revenue Growth YOY -26.20%
5-Year Revenue Growth 46.10%
Operating Margin Twelve Trailing Months -146.70%

Balance Sheet

Total Cash Most Recent Quarter 237,028,000
Total Cash Past Year 237,028,000
Total Cash Prior Year 292,005,000
Net Cash Position Most Recent Quarter 217,028,000
Net Cash Position Past Year 221,728,000
Long Term Debt Past Year 15,300,000
Long Term Debt Prior Year 15,300,000
Total Debt Most Recent Quarter 20,000,000
Equity to Debt Ratio Past Year 0.94
Equity to Debt Ratio Most Recent Quarter 0.92
Total Stockholder Equity Past Year 240,978,000
Total Stockholder Equity Prior Year 278,513,000
Total Stockholder Equity Most Recent Quarter 240,978,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -60,581,133
Free Cash Flow Per Share Twelve Trailing Months -2.23
Free Cash Flow Past Year -60,395,000
Free Cash Flow Prior Year -21,000,000

Options

Put/Call Ratio 0.49
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.15
MACD Signal -0.29
20-Day Bollinger Lower Band 9.06
20-Day Bollinger Middle Band 14.80
20-Day Bollinger Upper Band 20.54
Beta 3.41
RSI 58.53
50-Day SMA 19.79
150-Day SMA 22.73
200-Day SMA 25.40

System

Modified 5/5/2025 5:40:02 PM EST